Trial Information
Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.
Inclusion Criteria:
- Patients between the ages 18 and 75 years.
- Patients may be carriers of the Human Immunodeficiency Virus (HIV).
- Patients must have been diagnosed with precancerous lesion(s) of the vulva by tissue
sampling (biopsy-proven vulvar intraepithelial neoplasia grade II or III)
- Patients must be able to come to University Hospital for their initial appointment in
Gynecologic Oncology Clinic, and for the eight follow-up visits in that Clinic
required by the protocol.
Exclusion Criteria:
- Pregnant or patients who are breast feeding a baby.
- Patients who have been diagnosed with a vaginal yeast infection.
- Patients who have undergone prior surgery for precancerous lesion(s) of the vulva.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Principal Investigator
Bernadette Cracchiolo, MD, MPH
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Medicine and Dentistry New Jersey
Authority:
United States: Institutional Review Board
Study ID:
0120050348
NCT ID:
NCT00382330
Start Date:
Completion Date:
Related Keywords:
- Vulvar Cancer
- Vulva
- Vulvar Neoplasms
Name | Location |
University of Medicine and Dentistry of NJ |
Newark, New Jersey 07107 |